Results 31 to 40 of about 12,544,176 (238)

Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia.

Journal of Lipid Research, 1990
Familial defective apolipoprotein B-100 is a genetic disorder of apolipoprotein B-100 that causes moderate to severe hypercholesterolemia. A single amino acid mutation in apolipoprotein B diminishes the ability of low density lipoproteins to bind to the ...
TL Innerarity, RW Mahley, KH Weisgraber, TP Bersot, RM Krauss, GL Vega, SM Grundy, W Friedl, J Davignon, BJ McCarthy   +9 more
doaj   +1 more source

The effects of apolipoprotein B depletion on HDL subspecies composition and function[S]

Journal of Lipid Research, 2016
HDL cholesterol (HDL-C) efflux function may be a more robust biomarker of coronary artery disease risk than HDL-C. To study HDL function, apoB-containing lipoproteins are precipitated from serum.
W. S. Davidson, Anna Heink, Hannah Sexmith, J. Melchior, Scott M. Gordon, Z. Kuklenyik, L. Woollett, J. Barr, Jeffrey I. Jones, Christopher A. Toth, Amy S. Shah   +10 more
semanticscholar   +1 more source

Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men.

Journal of Lipid Research, 1996
Effectiveness of a simultaneous inhibition of cholesterol absorption and synthesis, caused by sitostanol ester margarine and pravastatin, was studied to control mild hypercholesterolemia in men with non-insulin-dependent diabetes mellitus (NIDDM) (n = 8).
H Gylling, T A Miettinen
doaj   +1 more source

Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study

BMC Endocrine Disorders, 2021
Background Apolipoprotein (Apo) may be associated with type 2 diabetes (T2D), however, little is known whether or not serum apolipoproteins are correlated with fasting blood glucose (FBG) and the prevalence of T2D in Chinese populations.
Liang Gao, Yaju Zhang, Xingmin Wang, Hongli Dong   +3 more
doaj   +1 more source

Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: what parameters should a basic lipid profile include?

Advances in Laboratory Medicine, 2023
Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice.
Arrobas Velilla Teresa, Guijarro Carlos, Ruiz Raquel Campuzano, Piñero Manuel Rodríguez, Valderrama Marcos José Francisco, Pérez Pérez Antonio, Botana López Antonio M., López Ana Morais, García Donaire José Antonio, Obaya Juan Carlos, Castilla-Guerra Luis, Carratalá Vicente Pallares, Cabello Isabel Egocheaga, Lazo Mercedes Salgueira, Castellanos Rodrigo María Mar, Mostaza Prieto José María, Gómez Doblas Juan José, Buño Soto Antonio,   +18 more
doaj   +1 more source

Clinical significance of leptin in systemic lupus erythematosus

Современная ревматология, 2021
Objective: to study the frequency of hyperleptinemia in patients with systemic lupus erythematosus (SLE), its relationship with clinical and laboratory manifestations of the disease, drug therapy, and other metabolic disorders.Patients and methods.
L. V. Kondratyeva, T. A. Panafidina, T. V. Popkova, Yu. N. Gorbunova, M. V. Cherkasova   +4 more
doaj   +1 more source

Low rates of apoB secretion from HepG2 cells result from reduced delivery of newly synthesized triglyceride to a “secretion-coupled” pool.

Journal of Lipid Research, 1996
The present study was aimed at defining the roles of intracellular triglyceride pools in apolipoprotein B secretion from HepG2 cells. Oleic acid (0.2 mmol/L) in the medium stimulated both triglyceride synthesis and apolipoprotein B secretion. Stimulation
X Wu, A Shang, H Jiang, H N Ginsberg
doaj   +1 more source

The Apolipoprotein B/Apolipoprotein A-I Ratio as a Potential Marker of Plasma Atherogenicity

Disease Markers, 2015
Background. The apolipoprotein (apo) B/apoA-I ratio represents the balance between apoB-rich atherogenic particles and apoA-I-rich antiatherogenic particles, and this ratio is considered to be a marker of cardiovascular risk.
A. M. Kaneva, N. Potolitsyna, E. Bojko, J. Odland   +3 more
semanticscholar   +1 more source

Lumican silencing ameliorates β-glycerophosphate-mediated vascular smooth muscle cell calcification by attenuating the inhibition of APOB on KIF2C activity

Open Medicine, 2023
Adverse cardiovascular events are associated with vascular calcification (VC) process, where vascular smooth muscle cells (VSMCs) differentiate into osteoblastic phenotype and deposit hydroxyapatite crystals. Microtubule-associated protein kinesin family
Li Haibin, Zhang Chunyan, Liu Qiang
doaj   +1 more source

Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins

Journal of Lipid Research, 2012
Mipomersen, an antisense oligonucleotide that reduces hepatic production of apoB, has been shown in phase 2 studies to decrease plasma apoB, LDL cholesterol (LDL-C), and triglycerides.
Jeremy D. Furtado, Mark K. Wedel, Frank M. Sacks   +2 more
doaj   +1 more source